Since the introduction of insulin almost a century ago, more than 80 peptide drugs have reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis …
SL Hauser, BAC Cree - The American journal of medicine, 2020 - Elsevier
Multiple sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of the central nervous system, and the leading cause of nontraumatic neurological disability in …
Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling current data to aid …
M Tintore, A Vidal-Jordana… - Nature Reviews …, 2019 - nature.com
The modern era of multiple sclerosis (MS) treatment began 25 years ago, with the approval of IFNβ and glatiramer acetate for the treatment of relapsing–remitting MS. Ten years later …
L Bierhansl, HP Hartung, O Aktas, T Ruck… - Nature reviews Drug …, 2022 - nature.com
Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system that causes demyelination, axonal degeneration and astrogliosis, resulting in progressive …
A Sharabi, MG Tsokos, Y Ding, TR Malek… - Nature reviews Drug …, 2018 - nature.com
Regulatory T (Treg) cells suppress inflammation and regulate immune system activity. In patients with systemic or organ-specific autoimmune diseases or those receiving …
The prevalence of multiple sclerosis (MS) and the age of affected patients are increasing owing to increased longevity of the general population and the availability of effective …
Background BG-12 (dimethyl fumarate) was shown to have antiinflammatory and cytoprotective properties in preclinical experiments and to result in significant reductions in …
S Meyer-Moock, YS Feng, M Maeurer, FW Dippel… - BMC neurology, 2014 - Springer
Background There are a number of instruments that describe severity and progression of multiple sclerosis and they are increasingly used as endpoints to assess the effectiveness of …